LTLena M. Thorn

Lena M. Thorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lena M. Thorn has a total of 351 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FinnDiane LifeOne Study: influence of ageing on people with type 1 diabetes – a prospective observational cohort study protocol

    by Jenna Nicklén, Susanna Satuli-Autere, Kaarina Rimpeläinen, Anu Dufva, Anni Ylinen, Emilia MC Franzén, Marika I Eriksson, Fanny Jansson Sigfrids, Hanna Öhman, Lena M Thorn

    Introduction: Life expectancy for people with type 1 diabetes has increased due to improved treatment of diabetes and its comorbidities, allowing many to reach old age. Still, we lack knowledge of how individuals with type 1 diabetes age. On one hand, those who reach older age can be considered survivors, but on the other hand their long-standing diabetes might still exhibit negative impacts on their health and functional ability. Healthy ageing is the WHO’s priority for this decade. The focus has shifted from chronological age to functional ability, which reflects the ability of individuals to perform meaningful activities. Functional ability is shaped by intrinsic capacity, the environment and their interaction. Intrinsic capacity encompasses five main domains: cognition, vitality, sensory function, locomotion and psychological domain. This observational study aims to assess how this vulnerable group of individuals with type 1 diabetes age and to identify factors that contribute to their healthy ageing, intrinsic capacity and its domains. Methods and analysis: The FinnDiane LifeOne Study is a prospective observational cohort study. We aim to recruit a minimum of 300 individuals with type 1 diabetes from the FinnDiane Study, aged >65 and a minimum of 100 matched controls without insulin-dependent diabetes. The cohort will be comprehensively characterised, including clinical assessment, laboratory tests, questionnaires and a geriatric assessment of different aspects of functioning ability, with 5 years intervals. We will compare the individuals with type 1 diabetes to their matched controls. For those with type 1 diabetes, we will further assess which factors from the FinnDiane baseline and trajectories during follow-up predict healthy ageing in above 65-year-olds. Ethics and dissemination: The LifeOne Study protocol is approved by the Ethics Committee of HUS Helsinki University Hospital (HUS/4387/2023) and the study adheres to the Declaration of Helsinki. Written informed consent is obtained from each participant. Findings will be published in international peer-reviewed journals with an open access choice. Trial registration number: NCT07289204 .

  • Open Access

    Lipids and apolipoproteins affect the risk of ST-elevation and non-ST-elevation myocardial infarctions differently in type 1 diabetes: a nationwide finnish cohort study

    by Patrik Smidtslund, Fanny Jansson Sigfrids, Valma Harjutsalo, Ville Thorn, Marja-Riitta Taskinen, Per-Henrik Groop, Lena M Thorn

  • Open Access

    Multimorbidity and the Number of Conditions Increase With the Duration of Type 1 Diabetes and Associate With Increased Mortality

    by Anni Ylinen, Stefan Mutter, Stefanie Hägg‐Holmberg, Susanna Satuli‐Autere, Valma Harjutsalo, Per‐Henrik Groop, Lena M. Thorn

    Background: Multimorbidity in type 1 diabetes has previously not been studied in detail. Therefore, we aimed to assess the prevalence of multimorbidity and its association with mortality in type 1 diabetes. Methods: This observational follow‐up study includes 4069 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy study. The prevalence of multimorbidity (coexistence of two or more chronic conditions) was based on 32 conditions at baseline. Conditions were grouped into three subcategories: vascular comorbidities, autoimmune disorders, and other conditions. Hazard ratios (HR) for all‐cause mortality were calculated. Results: The prevalence of multimorbidity was 60.4% and increased with age and especially diabetes duration. Multimorbidity was associated with increased risk of mortality, HR 6.0 (95% CI 4.6–7.8), p < 0.001. The HR for mortality increased by each additional condition and was 37.9 (95% CI 25.7–56.0) in those with ≥eight conditions. Vascular comorbidities and other conditions were associated with increased mortality, HRs 5.9 (4.4–7.9) and 3.8 (2.4–5.9), p < 0.001, separately, and in combination, HR 11.2 (8.3–15.2), p < 0.001. Autoimmune disorders did not influence mortality. Conclusions: Multimorbidity in type 1 diabetes is common and is associated with increased mortality. Comprehensive evaluation of all additional conditions is needed to tailor treatment individually.

  • Open Access

    WELL-ED: Wellbeing and Education linkages in school-aged children - A protocol for a population-based register study and survey of adolescents

    by Silja Kosola, Sanna Salonen, Jenni Miettinen, Iiris Hörhammer, Anna-Riikka Impiö, Satu M. Kumpulainen, Johanna Sergejeff, Saija Numari, Pirjo Laitinen-Parkkonen, Maria Tapola-Haapala, et al.

    Introduction: Education is a core social determinant of health for children and adolescents. Unfortunately, academic achievement, health, and wellbeing of adolescents have decreased in many developed countries in the past decade. The purpose of the Wellbeing and Education linkages in school-aged children (WELL-ED) study is to examine associations of school absences and academic achievement with use of school-based and community-based health and social welfare services. In addition, we will assess user experiences and multi-sector services pathways of school-aged children for a better understanding of how the service system could respond to the needs of children. Methods and analysis: WELL-ED is a large population-based study that combines register data on school absences and educational support from municipalities with register data on healthcare and social service use collected from wellbeing services counties in Finland. The study cohort includes all children who attended mandatory education in public schools in Southern Finland in school year 2023-2024. A smaller cohort of adolescents in school year 8 was invited to complete a user experience survey. The primary outcomes of this study are related to equity of service use. Ethics and dissemination: The Regional Committee on Medical Research Ethics of the Helsinki and Uusimaa Hospital District (2803/2024) has approved the WELL-ED study protocol. For the survey, adolescents in year 8 and parents of adolescents younger than 15 provided informed consent. Results will be published in peer-reviewed journals, summaries will be sent to participating municipalities and wellbeing services counties and press releases will be written on key findings.

  • Open Access

    FinnDiane LifeOne Study - Impact of ageing on people with type 1 diabetes, a prospective observational cohort study

    by Jenna Nicklén, Susanna Satuli-Autere, Kaarina Rimpeläinen, Anu Dufva, Anni Ylinen, Emilia M.C. Franzén, Marika I. Eriksson, Fanny Jansson Sigfrids, Hanna Öhman, Lena M. Thorn

    Introduction: Life expectancy for people with type 1 diabetes has increased due to improved treatment of diabetes and its comorbidities, allowing many to reach old age. Still, we lack knowledge of how individuals with type 1 diabetes age. On one hand, those who reach older age can be considered survivors, but on the other hand their long-standing diabetes might still exhibit negative impacts on their health and functional ability. Healthy ageing is the World Health Organization’s priority for this decade. The focus has shifted from chronological age to functional ability, which reflects the ability of individuals to perform meaningful activities. Functional ability is shaped by intrinsic capacity, the environment, and their interaction. Intrinsic capacity encompasses five main domains: cognition, vitality, sensory function, locomotion, and psychological domain. This observational study aims to assess how this vulnerable group of individuals with type 1 diabetes age and to identify factors that contribute to their healthy ageing, intrinsic capacity, and its domains. Methods and analysis: The FinnDiane LifeOne Study is a prospective observational cohort study. We aim to recruit a minimum of 300 individuals with type 1 diabetes from the FinnDiane Study, aged >65, and a minimum of 100 matched controls without insulin-dependent diabetes. The cohort will be comprehensively characterized, including clinical assessment, laboratory tests, questionnaires, and a geriatric assessment of different aspects of functioning ability, with five years intervals. We will compare the individuals with type 1 diabetes to their matched controls. For those with type 1 diabetes, we will further assess which factors from the FinnDiane baseline and trajectories during follow-up predict healthy ageing in above 65-year-olds. Ethics and dissemination: The LifeOne study protocol is approved by the Ethics Committee of HUS Helsinki University Hospital (HUS/4387/2023) and the study adheres to the Declaration of Helsinki. Written informed consent is obtained from each participant. Findings will be published in international peer-reviewed journals with an open access choice. The study is registered at ClinicalTrials.gov with ID NCT07289204 . STRENGTHS AND LIMITATIONS OF THE STUDY: This is a prospective observational cohort study with a matched control group. For the participants with type 1 diabetes, we have unique and comprehensive longitudinal clinical and genetic data available from approximately participants’ middle age, enabling identification of factors that contribute to their healthy ageing, while accounting for the competing risk of death. The cohort is thoroughly characterised regarding diabetes, cardiometabolic health, lifestyle, psychosocial factors, and includes a geriatric assessment, thereby enabling comparison of impact of ageing between individuals with type 1 diabetes and controls without insulin-dependent diabetes. The cohort is Caucasian with recruitment from Southern Finland, potentially limiting generalisability to other more ethnically diverse populations.

  • Open Access

    Association between chronic low-grade inflammation and metabolic syndrome and their impact on the risk of coronary artery disease in type 1 diabetes

    by Johanna M. Blomqvist, Marika I. Eriksson, Valma Harjutsalo, Patrik Smidtslund, Per-Henrik Groop, Lena M. Thorn


  • Open Access

    Waist-to-Height Ratio Is Associated With the Risk of Coronary Artery Disease in Type 1 Diabetes: A 19-Year Cohort Study

    by Erika Bezerra Parente, Fanny Jansson Sigfrids, Per-Henrik Groop, Lena M. Thorn, Niina Sandholm, Valma Harjutsalo, FinnDiane Study Group*

    Obesity, kidney disease, and coronary artery disease (CAD) are interconnected. Here, the relationship between central obesity and CAD across albuminuria categories in type 1 diabetes was investigated. Data on 4,349 individuals without prior CAD from the Finnish Diabetic Nephropathy Study were analyzed. Central obesity was defined as waist-to-height ratio (WHtR) ≥0.5. Outcomes included acute myocardial infarction, coronary revascularizations, and CAD-related death. Associations were assessed with Cox regression adjusted for baseline covariates. Over a median 19-year follow-up, 664 CAD events (15.3%) occurred. The 10- and 20-year cumulative CAD incidences were 11.6% and 25.3%, respectively, in those with central obesity versus 4.4% and 9.9% without, respectively. In multivariable analysis, the hazard ratio for CAD per 0.1-unit WHtR increase was 1.21 (95% CI, 1.06–1.38; P = 0.006) overall and 1.26 (95% CI, 1.02–1.56; P = 0.03) among those without albuminuria. In conclusion, WHtR is associated with increased CAD risk in type 1 diabetes, particularly among those without albuminuria.


  • Shrunken Pore Syndrome and Risk of Cardiovascular Disease and All-Cause Mortality in Individuals With Type 1 Diabetes With and Without Albuminuria

    by Valma Harjutsalo, Lena M. Thorn, Niina Sandholm, Per-Henrik Groop

    OBJECTIVE: To investigate the association between “shrunken pore syndrome” (SPS), defined as a large discrepancy between estimated glomerular filtration rates based on cystatin C (eGFRcys) and creatinine (eGFRcr), and coronary artery disease (CAD), stroke, peripheral artery disease (PAD), heart failure (HF), and all-cause mortality in individuals with T1D with and without albuminuria. RESEARCH DESIGN AND METHODS: The study comprised 3,769 individuals with and without albuminuria from the Finnish Diabetic Nephropathy Study (FinnDiane) who had both serum creatinine (Scr) and serum cystatin C (SCysC) data available. RESULTS: SPS (eGFRcys/eGFRcr ratio cutoff 0.7) was not associated with CAD or stroke. In those with SPS but without albuminuria, the hazard ratios (HRs) for HF, PAD, and all-cause mortality were 3.07 (95% CI 1.47–6.38), 3.64 (95% CI 1.75–7.57), and 3.08 (95% CI 1.86–5.11). The associations between the eGFRcys/eGFRcr ratio as a continuous variable, as well as eGFRcys alone and HF, PAD, and all-cause mortality were significant in those without albuminuria. In individuals with albuminuria, SPS was only associated with HF (HR 1.54; 95% CI 1.02–2.33), whereas the eGFRcys/eGFRcr ratio as a continuous variable was not associated with any of the outcomes. On the contrary, both eGFRcys and eGFRcr were independently associated with all studied outcomes in those with albuminuria. CONCLUSIONS: Findings highlight the clinical potential of identifying individuals at increased risk of HF, PAD, and all-cause mortality at an early stage among those with T1D without albuminuria by evaluating both eGFRcys and eGFRcr and their discrepancy.

  • Open Access

    Associations between retinal microvasculature and cognition in middle-aged adults with type 1 diabetes without overt neurological symptoms

    by Iiris Kyläheiko, Aleksi Tarkkonen, Linda Kuusela, Juha Martola, Teemu I. Paajanen, Jussi Virkkala, Ward Fickweiler, George L. King, Jennifer K. Sun, Joni A. Turunen, et al.